Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Thought Leadership
Latest Report
Evaluate Vantage Biopharma and Venture Capital: A Deep Dive
The sheer amount of private capital available to young drug developers the last few years is nothing new, however the Covid-19 pandemic has brought about an unprecedented influx of new money into biopharma. How permanent will these new funds prove; is biopharma's importance and attributes finally being realised by investors, governments and…
Report library
Evaluate Vantage Report: US Approvals Under the Spotlight
On April 27-29, a three-day US advisory committee meeting convenes. Their objective is to scrutinise the accelerated approvals of certain anti-PD-(L)1 drugs whose…
Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review
Despite the initial shock of the COVID-19 pandemic, 2020 was a standout year for biopharma. The top 600 biopharma companies added $487bn in market capitalisation, and…
Evaluate Vantage 2021 Preview
Biopharma’s role in trying to bring the COVID-19 pandemic to an end has made household names of companies large and small, and cutting-edge technologies like mRNA…
Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020
Biopharma was not exempt from the initial shock of a global pandemic, but the worst projections have not happened and the initial beneficiaries have now emerged. After a…
Evaluate Pharma World Preview 2020, Outlook to 2026
This year's edition of the Evaluate Pharma World Preview arrives at a time when the global economy is reeling. The impact of COVID-19 has so far wiped $7.85bn off…
